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Research MicroRNA, hsa-miR-200c, is an independent 
prognostic factor in pancreatic cancer and its 
upregulation inhibits pancreatic cancer invasion 
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Abstract
Background: Recently, the microRNA-200 family was reported to affect cancer biology by regulating epithelial to 
mesenchymal transition (EMT). Especially, the expression of miR-200c has been shown to be associated with 
upregulating the expression of E-cadherin, a gene known to be involved in pancreatic cancer behavior. However, the 
significance of miR-200c in pancreatic cancer is unknown.
Methods: In the present study, we investigated the relationship between E-cadherin and miR-200c expression in a 
panel of 14 pancreatic cancer cell lines and in macro-dissected formalin-fixed paraffin-embedded (FFPE) tissue samples 
obtained from 99 patients who underwent pancreatectomy for pancreatic cancer. We also investigated the effects of 
miR-200c on the proliferation and invasion of pancreatic cancer cells.
Results: We found that patients with high levels of miR-200c expression had significantly better survival rates than 
those with low levels of miR-200c expression. We also found a remarkably strong correlation between the levels of miR-
200c and E-cadherin expression.
Conclusions: These data indicate that miR-200c may play a role in the pancreatic cancer biology and may be a novel 
marker for the prognosis of pancreatic cancer.
Introduction
Pancreatic cancer is the fifth leading cause of cancer
death and has the lowest survival rate of any solid cancer
in the industrialized countries [1,2]. In the past 20 years,
6942 Japanese patients with pancreatic cancer who
underwent pancreatectomy showed a very poor progno-
sis with an overall median survival time (MST) of 11.7
months and a 5-year survival rate of 13.4% [1]. Extensive
molecular analysis of pancreatic cancer has led to discov-
eries of genetic, epigenetic and, more recently, microRNA
alterations [3-6].
MicroRNAs (miRNAs) are endogenous, small non-
coding RNAs of 14-24 nucleotides that can negatively
regulate protein expression at the post-transcriptional
level by translational inhibition and/or mRNA degrada-
tion, mostly through base pairing with the 3'-UTR of
their target mRNAs [7]. Recently, the abnormal expres-
sion of miRNAs was shown to be correlated with cancer.
The first evidence suggesting a direct link between miR-
NAs and human cancer was the localization of miR-15a
and miR-16-1 within a 30 kb region of minimal loss on
chromosome 13 that is deleted in chronic lymphocytic
leukemia (CLL) and that both genes are often deleted or
down-regulated in CLL [8]. Other miRNAs, such as miR-
143  and  miR-145  have reduced levels of expression in
adenomatous and cancerous stages of colorectal neopla-
sia [9], while let-7 expression is reduced in lung tumor
[10]. The first oncogenic miRNAs (oncomiR-1), the miR-
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17-92 cluster, named from the research on human B cell
lymphomas [11], were described as tumor suppressors or
oncogenes and brought a novel area of investigation to
cancer research [12,13].
R e c e n t l y ,  i t  h a s  b e e n  r e p o r t e d  t h a t  miR-200c  is a
marker of aggressiveness and chemoresistance in female
reproductive cancers, that miR-200c suppresses invasive-
ness and restores sensitivity to microtubule-targeting
chemotherautic agents in breast and ovrian cancer cells,
and that downregulation of miR-200c links breast cancer
stem cells with normal stem cells [14-16]. Meanwhile,
Hurteau et al. revealed that over-expression of miR-200c
leads to reduced expression of transcription factor 8
(TCF8; also termed ZEB1) and increased expression of E-
cadherin in breast cancer cells [17,18]. Also, Park et al.
reported that miR-200c regulates epithelial to mesenchy-
mal transition (EMT) and restores expression of E-cad-
herin in breast and ovarian cancer cells [18-20]. EMT is a
central process in the progression of primary tumors
toward metastasis (a switch from the polarized, epithelial
phenotype to a highly motile fibroblastoid or mesenchy-
mal phenotype). Furthermore, expression of E-cadherin
can predict disease outcome in patients with resectable
pancreatic carcinoma, and the therapeutic restoration of
E-cadherin was proposed as a strategy to suppress cancer
metastasis [21-24].
In the present study, to identify novel relationship
between E-cadherin and miR-200c in pancreatic cancer,
we quantified miR-200c expression in a panel of 14 pan-
creatic cancer cell lines and in 99 samples of macro-dis-
sected formalin-fixed paraffin-embedded (FFPE)
pancreatic tissues. We also investigated the in vitro
effects of miR-200c upregulation on the proliferation and
i n v a s i o n  o f  p a n c r e a t i c  c a n c e r  c e l l s .  W e  f o u n d  t h a t
patients with high levels of miR-200c expression had sig-
nificantly better survival rates compared to those with
low levels of miR-200c expression. We also found striking
correlation between with the levels of miR-200c and E-
cadherin expression. These data suggest that miR-200c
may be a novel marker for the prognosis of pancreatic
cancer.
Materials and methods
Cultured cells
The following 15 pancreatic cancer cell lines were stud-
ied: AsPC-1, KP-1N, KP-2, KP-3, PANC-1, BxPC-3 and
SUIT-2 (provided by Dr. H. Iguchi, National Shikoku
Cancer Center, Matsuyama, Japan); MIA PaCa-2 (Japa-
nese Cancer Resource Bank, Tokyo, Japan); NOR-P1
(established in our laboratory by Dr. Sato); CAPAN-1,
CAPAN-2, CFPAC-1, H48N, HS766T and SW1990
(American Type Culture Collection, Manassas, VA,
USA). In addition, a human pancreatic ductal epithelial
cell line (HPDE, provided by Dr. Ming-Sound Tsao, Uni-
versity of Toronto, Toronto, Ontario, Canada) was stud-
ied. The cells were maintained as described previously
[25].
Pancreatic tissues
Our study consisted of 99 patients who underwent pan-
creatic resection for pancreas cancer at the Department
of Surgery and Oncology, Kyushu University Hospital
(Fukuoka, Japan) from 1992 to 2007. The patients com-
prised 64 men and 35 women with a median age of 66
years (range, 36-86 years). Survival was measured from
the time of pancreatic resection and death was the end-
point. Prognosis was examined in October 2008. The
median observation time for overall survival was 15
months and it ranged from 1 to 101 months. Sixty four
patients died during follow-up and the other patients
were alive and censored.
All resected specimens were fixed in formalin and
embedded in paraffin (FFPE) for pathological diagnosis.
All tissues adjacent to the specimens were evaluated his-
tologically according to the criteria of the World Health
Organization. For all cases, two pathologists were in
agreement with regard to pathological features and both
confirmed the diagnoses. The stage of tumors was
assessed according to the Union Internationale Contre le
Cancer (UICC) classification. The clinicopathological
characteristics of the tumor collection are described in
Table 1. Written informed consent was obtained from all
patients, and the study was approved by the Ethics Com-
mittee of Kyushu University and conducted according to
the Ethical Guidelines for Human Genome/Gene
Research enacted by the Japanese Government and the
Helsinki Declaration.
miRNA isolation
miRNAs were extracted from cultured cells using a mir-
Vana™ miRNA Isolation Kit (Ambion, Austin, TX, USA)
and from macro-dissected FFPE pancreatic tissues using
an RNeasy® FFPE Kit (Qiagen, Tokyo, Japan), following
the manufacturer's instructions. Considering the influ-
ence of genomic DNA contamination, especially from the
FFPE materials, Qiagen provides a special gDNA Elimi-
nator spin column to rapidly remove genomic DNA, and
we also performed a DNase digestion step. The extracted
RNA was quantified by absorbance at 260 nm and its
purity was evaluated by the absorbance ratio at 260/280
nm with a NanoDrop ND-1000 spectrophotometer (Nan-
oDrop Technologies, Rockland, DE, USA).
Quantitative real-time reverse-transcription polymerase 
chain reaction (qRT-PCR)
The expression of miR-200c and RNU6B (U6 snRNA, a
reference gene) was measured by qRT-PCR using a Taq-
Man® MicroRNA Reverse Transcription Kit and TaqMan®Yu et al. Molecular Cancer 2010, 9:169
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Universal PCR Master Mix (No AmpErase®  UNG;
Applied Biosystems, Tokyo, Japan) and a Chromo4™ Sys-
tem (Bio-Rad, Hercules, CA, USA). We followed the
manufacturer's protocols to perform two-step real-time
RT-PCR for the measurement of miR-200c and RNU6B
expression. Each sample was run in triplicate. The level of
miR-200c  expression was calculated from a standard
curve constructed with small RNAs from the CAPAN-1
pancreatic cancer cell line. The expression levels of miR-
200c were normalized against the corresponding expres-
sion levels of RNU6B.
The levels of E-cadherin mRNA and 18S rRNA were
measured by qRT-PCR using a QuantiTect SYBR Green
RT-PCR Kit (Qiagen, Tokyo, Japan) and a Chromo4™ Sys-
tem, following the manufacturer's protocols [26]. Each
sample was run in triplicate. We designed specific prim-
ers for E-cadherin  (forward, 5'-tcagcgtgtgtgactgtgaa-3';
reverse, 5'-aggctgtgccttcctacaga-3'), and 18S rRNA (for-
ward, 5'-ctttcgaggccctgtaattg-3'; reverse, 5'-cctccaatggatc-
ctcgtta-3') using Primer 3 software and performed
BLAST searches to ensure the specificity of the primers.
The PCR products amplified using these primers are
small (18S rRNA, 63 bp; E-cadherin, 53 bp), which
allowed accurate and sensitive qRT-PCR despite the frag-
mented RNA extracted from FFPE tissue specimens
[27,28]. We also included controls without reverse tran-
scriptase to confirm that there was no influence from
genomic DNA contamination. The level of E-cadherin
mRNA was calculated from a standard curve constructed
with total RNA from CAPAN-1 cells and normalized
against levels of 18S  rRNA. Accuracy and integrity of
PCR products were confirmed with an Agilent 1000 Bio-
analyzer (Agilent Technologies, Palo Alto, CA, USA).
Cell transfection with miRNA precursors
Upregulation of miR-200c  expression was achieved by
transfection with the hsa-miR-200c precursor (Pre-miR™
miRNA Precursor; Applied Biosystems). To verify the
specificity of the transfection effect, we used a Pre-miR™
miRNA Precursor Negative Control (Applied Biosys-
tems). Transfections were performed by electroporation
using a Nucleofector system (Amaxa Biosystems, Köln,
Germany) according to the manufacturer's instructions.
PANC-1, SUIT-2 and KP-2 cells (1-2 × 106) were trans-
fected with 100 pmol of the indicated precursor or nega-
tive control. The degree of mature miR-200c upregulation
48 h after transfection was verified by quantifying the
expression level of mature miR-200c. Cells harvested 48 h
after transfection were also used for cell proliferation or
invasion assays.
Propidium iodide (PI) assay
Cell proliferation was evaluated using a multiwell fluores-
cence plate reader and a previously described method
[29] with modifications [30,31]. Briefly, cancer cells were
seeded at 2 × 104 cells/well in Falcon flat-bottom 24-well
plates (Becton Dickinson, Franklin Lakes, NJ, USA). 30
μM PI (Wako Ltd., Osaka, Japan) and 600 μM digitonin
(Wako Ltd.) were then added to each well. After incuba-
tion for 90 min of at 37°C, the fluorescence intensities of
labeled nuclei were measured using a CYTO Fluor™ II flu-
orescence multiwell plate reader (PerSeptive Biosystems,
Framingham, MA, USA) to determine total cell numbers.
Table 1: Clinicopathological Characteristics of 99 Patients 
with Pancreatic Cancer
Median age 65.7 years (range, 36-86 years)
Sex (Male/Female) 62 (62.6%)/37 (37.4%)
Histological diagnosis
Adenocarcinoma 97 (98.0%)
Adenosquamous 
carcinoma
2 (2.0%)
pT category
pT1 6 (6.1%)
pT2 3 (3.0%)
pT3 57 (57.6%)
pT4 33 (33.3%)
pN category
pN0 33 (33.3%)
pN1 66 (66.7%)
UICC stage
IA & IB 5 (5.1%) & 4 (4.0%)
IIA & IIB 21 (21.2%) & 64 (64.7%)
III 1 (1.0%)
IV 4 (4.0%)
Histological grade
G1 20 (20.2%)
G2 43 (43.4%)
G3 36 (36.4%)
Residual tumor category
R0 60 (61.2%)
R1 38 (38.7%)
Vessel invasion
Positive 61 (62.2%)
Negative 37 (37.7%)
Neural invasion
Positive 84 (84.8%)
Negative 15 (15.2%)Yu et al. Molecular Cancer 2010, 9:169
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In vitro Matrigel invasion assay
Invasion of pancreatic cancer cells was evaluated by the
numbers of cells invading Matrigel-coated transwell
inserts (Becton Dickinson) as reported previously [25,32].
Briefly, transwell inserts with 8 μm pores were coated
with Matrigel (20 μg/well; Becton Dickinson). Cancer
cells were seeded in the upper chamber at a density of 1.0
× 105 cells/cm2 in 250 μl of Dulbecco's modified Eagle's
medium (DMEM) supplemented with 10% fetal bovine
serum (FBS). After incubation at 37°C, cells that had
invaded to the lower surface of the Matrigel-coated mem-
branes were fixed with 70% ethanol, stained with hema-
toxylin and eosin (H & E) and counted in five randomly
selected fields under a light microscope.
Statistical analysis
The in vitrodata are presented as mean values with error
bars representing the minimum and maximum or with
the standard deviation (SD). The significance level was p
< 0.05. MiR-200c  expression in macro-dissected FFPE
samples was split into high and low expression groups
using a recursive descent partition analysis. Categorical
variables were compared with the chi-square test
(Fisher's exact probability test). Survival curves were con-
structed with the Kaplan-Meier product-limit method
and compared by log-rank tests. To evaluate independent
prognostic factors associated with survival, a multivariate
Cox proportional hazards regression analysis was used,
with  miR-200c  expression, age, sex pathological tumor
(pT) status, pathological node (pN) status, UICC stage,
residual tumor (R) status, histological grade (G) and ves-
sel invasion as covariates (Table 2). Statistical significance
was defined as p < 0.05. The statistical analyses in the
macro-dissected FFPE samples were performed with JMP
7.01 software (SAS Institute, Cary, NC, USA).
Results
Quantitative analysis of miR-200c expression in pancreatic 
cancer cell lines
We investigated miR-200c  expression in 15 pancreatic
cancer cell lines and in a non-neoplastic ductal epithelial
cell line (HPDE) by quantitative real-time RT-PCR. As
shown in Figure 1a, 4 pancreatic cancer cell lines,
CAPAN-1, SW1990, CFPAC-1, and H48N, expressed
higher levels of miR-200c  than HPDE. Two pancreatic
cancer cell lines, AsPC-1 and CAPAN-2, expressed simi-
lar levels of miR-200c to HPDE and 9 pancreatic cancer
cell lines, BxPC-3, NOR-P1, KP-1N, KP-2, KP-3, Hs766T,
SUIT-2, PANC-1 and MIA PaCa-2, expressed lower levels
of miR-200c than HPDE.
High levels of miR-200c expression correlated with low 
invasion ability
Having determined the levels of miR-200c expression in
the 15 pancreatic cancer cell lines, we investigated the
invasion ability of the cell lines that expressed high levels
of miR-200c (CAPAN-1, CFPAC-1, and H48N) and of the
cell lines that expressed low levels of miR-200c (KP-3,
SUIT-2, and PANC-1) using the Matrigel invasion assay.
We seeded 7.5 × 104 cells per Matrigel-coated well and
counted the cells that had invaded the Matrigel 50 h after
s e e d i n g .  A s  s h o w n  i n  F i g u r e  1 b ,  a l l  c e l l  l i n e s  t h a t
expressed high levels of high miR-200c  (CAPAN-1,
CFPAC-1, and H48N) showed fewer numbers of invading
cells compared to the cell lines that expressed low levels
of low miR-200c (KP-3, SUIT-2, and PANC-1).
Table 2: Univariate and Multivariate Survival Analyses
Univariate analysis Multivariate analysis
Characteristics Hazard Ratio (HR) 95% confidence interval P value Hazard Ratio (HR) 95% confidence interval P value
Age (< 65) 0.9 0.5 - 1.4 0.62 0.8 0.5 - 1.4 0.50
Sex(Female) 0.9 0.5 - 1.5 0.63 0.9 0.5 - 1.6 0.69
pT (pT1/2) 2.2 1.4 - 3.6 < 0.001 1.8 0.5 - 5.4 0.35
pN (negative) 0.4 0.2 - 0.7 < 0.001 0.5 0.3 - 1.0 0.06
UICC stage - - 0.003 - - 0.01
Histological grade (G3) 1.7 0.9 - 2.8 0.07 0.8 0.6 - 2.6 0.8
Residual tumor 
(positive)
3.0 1.8 - 5.0 < 0.001 3.2 1.8 - 5.8 < 0.001
Vessel invasion 
(positive)
2.3 1.4 - 4.1 0.001 1.9 1.0 - 3.6 0.03
Low miR-200c 1.8 1.0 - 3.5 0.03 2.2 1.1 - 4.6 0.02
Relative risk of UICC stage was not shown because of 2 parameters.Yu et al. Molecular Cancer 2010, 9:169
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Quantitative analysis of E-cadherin mRNA levels in cell lines 
and significant correlations between miR-200c and E-
cadherin mRNA levels
We investigated E-cadherin mRNA levels by qRT-PCR in
the 15 pancreatic cancer cell lines and in the HPDE cell
line. Similar to the results of miR-200c expression, there
were high or low E-cadherin mRNA levels in these cell
lines (Figure 2a), and we found there were significant cor-
relations between miR-200c and E-cadherin mRNA levels
in all cell lines (Pearson's test p < 0.0001, Figure 2b)
Upregulation of miR-200c in pancreatic cancer cell lines
To upregulate the expression of mature miR-200c, we
transfected the pancreatic cancer cell lines that expressed
miR-200c at low levels with the miR-200c precursor. 24 h
after transfection, we isolated total RNA (including small
RNAs) and investigated the levels of miR-200c expres-
sion. As shown in Figure 3a, SUIT-2 cells transfected with
the hsa-miR-200c precursor (precursor group) showed a
38-fold increase in mature miR-200c  expression com-
pared with cells transfected with the miRNA Precursor
Negative Control (control group). Similar increases of
miR-200c expression were seen in KP-3 and PANC-1 cell
lines (data not shown).
Upregulation of miR-200c enhanced the levels of E-cadherin 
mRNA in pancreatic cancer cells
We also investigated the levels of E-cadherin mRNA in
the precursor and control groups. As shown in Figure 3b,
the SUIT-2 precursor group, which expressed miR-200c
at levels 38-fold higher than the control group, showed
3.9-fold higher E-cadherin mRNA levels compared to the
control group 24 h after transfection.
Upregulation of miR-200c stimulated proliferation in cancer 
cells
After confirmation of the upregulation of miR-200c  in
pancreatic cancer cells, we monitored changes in cell pro-
liferation in PANC-1, SUIT-2, and KP-3 cell lines. As
shown in Figure 4a, the upregulation of mature miR-200c
expression in the precursor group enhanced cell prolifer-
ation in an upregulation rate-dependent manner for 96 h
after transfection in SUIT-2 cells (upper), and for 120 h in
KP-3 (middle) and PANC-1 cells (bottom).
Upregulation of miR-200c inhibited invasion of cancer cells
Next, we investigated the effect of upregulation of mature
miR-200c expression on the invasive potential of pancre-
atic cancer cells. Representative microphotographs of
cells invading through Matrigel-coated membranes 36 h
after transfection are shown for the control and miR-200c
precursor cells in the left and right panels of Figure 4b,
respectively. The numbers of invading PANC-1 cells were
Figure 1 The levels of miR-200c expression in cell lines and the 
correlation of miR-200c expression level and the invasion ability 
of pancreatic cancer cell lines. a. The levels of miR-200c expression in 
15 pancreatic cancer cell lines and in an HPDE cell line. b. Pictures of in-
vading cells from cell lines expressing high levels of miR-200c (CAPAN-
1, CFPAC-1 and H48N) and from cell lines expressing low levels of miR-
200c (KP-3, SUIT-2 and PANC-1). H & E staining. Original magnification, 
10 ×. Each sample was run in triplicate. Error bars represent SD.
a
b
Figure 2 E-cadherin expression in cell lines and the correlation 
between E-cadherin and miR-200c expression. a. The levels of miR-
200c expression in 15 pancreatic cancer cell lines and in an HPDE cell 
line. b. The correlation between miR-200c and E-cadherin mRNA levels 
in all cell lines (p < 0.0001). Each sample was run in triplicate. Error bars 
represent SD.
a
bYu et al. Molecular Cancer 2010, 9:169
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significantly inhibited in an upregulation rate-dependent
manner when cells were transfected with the miR-200c
precursor (p < 0.001), and the number of cells invading in
the precursor group was approximately 75% less than the
number of cells invading in the control group (Figure 4c).
Similar to the inhibition rate of the PANC-1 precursor
group, the KP-3 precursor group also showed a signifi-
cant inhibition of invasion compared to the control
group, with the control group invasion rate inhibited in
the precursor group by approximately 75% (Figure 4d, e).
Quantitative analysis of miR-200c and E-cadherin mRNA 
levels in macro-dissected FFPE pancreatic cancer tissues
We measured miR-200c versus E-cadherin mRNA levels
in macro-dissected FFPE samples from 99 patients who
underwent pancreatic resection for pancreatic cancer at
our institution from 1992 to 2007. The median miR-200c
expression level in the macro-dissected pancreatic cancer
samples was 0.30, and the median E-cadherin expression
level was 4.41. Similar to the results from cultured cells,
we also found that there was a significant correlation
between  miR-200c  and  E-cadherin  mRNA levels in all
macro-dissected pancreatic cancer tissues (Pearson's test
p < 0.0001, Figure 5a).
Univariate and multivariate analyses of miR-200c 
expression for survival time of patients with pancreatic 
cancer after curative resection
We classified the patients into two groups of high versus
low miR-200c expression (cut-off value: 0.64; the partition
was constructed by the overall survival time). The high
and low miR-200c expression groups were composed of
21 and 78 cases, respectively. In univariate survival analy-
ses based on the Cox proportional hazard model, the
miR-200c  levels and conventional prognostic factors,
such as pT status (pT3 and pT4 versus pT1 and pT2), pN
status (pN1 versus pN0), UICC stage (IV, III and IIB ver-
sus IIA, and versus IA and IB), tumor grade (G3 versus
G1 and G2), R factor (R1 versus R0) and vessel invasion
(positive versus negative), were investigated for overall
survival (Table 2). We found that pT status, pN status,
UICC stage, R factor and vessel invasion were signifi-
cantly associated with a shorter overall survival (p  <
0.001, p  < 0.001, p  = 0.002, p  < 0.001, and p = 0.001,
respectively). We also found that high miR-200c expres-
sion was associated with a longer overall survival (p =
0.03). The median survival time (MST) and 5-year sur-
vival rate were 42 months and 33.5% in the high miR-200c
expression group, and 19 months and 11.2% in the low
miR-200c expression group, respectively (Figure 5b). In
multivariate survival analyses, we found that the overall
survival time was significantly dependent on UICC stage
(p = 0.01), R factor (p < 0.001), vessel invasion (p = 0.03)
and high miR-200c expression (p = 0.02).
Discussion
The present study shows, for the first time, the involve-
ment of miR-200c in pancreatic cancer progression and
prognosis. We have found that high miR-200c expression
was related to low invasion ability, and that upregulation
of miR-200c expression inhibited cell invasion and stimu-
lated cell proliferation in pancreatic cancer cell lines. We
also have found a significant correlation between miR-
200c and E-cadherin expression, and that upregulation of
miR-200c  expression correlated with increased expres-
sion of E-cadherin in pancreatic cancer cell lines. This
finding is consistent with previous reports investigating
other cancers [14-19]. On the other hand, reduced
expression of E-cadherin is regarded as a main molecular
event in the dysfunction of the cell-cell adhesion system,
triggering cancer invasion and metastasis [33,34].
Recently, Liu et al. revealed that E-cadherin stimulated
cell proliferation at intermediate seeding densities, and
Mees  et al. revealed that metastasis suppressor gene
EP300 was regulated by miR-200c in ductal adenocarci-
nomas of the pancreas [35,36]. These studies indicate that
Figure 3 Upregulation of miR-200c in pancreatic cancer cell lines 
and enhanced expression of E-cadherin. a. SUIT-2 cells were trans-
fected with hsa-miR-200c precursor and showed a 38-fold increase in 
mature miR-200c expression compared with the control 24 h after 
transfection. b. Upregulation of miR-200c enhanced expression of E-
cadherin 3.9-fold relative to the control group. Each sample was run in 
triplicate. Error bars represent SD.
a
bYu et al. Molecular Cancer 2010, 9:169
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miR-200c plays a key role in the enhancement of prolifer-
ation and inhibition of invasion in pancreatic cancer via
regulation of E-cadherin. Such inconsistent function is
similar to gamma-interferon, which can inhibit tumor
growth and enhance metastasis in a TS/A mammary ade-
nocarcinoma model [37].
Furthermore, univariate and multivariate analyses of 99
macro-dissected FFPE pancreatic cancer samples
revealed that high miR-200c expression was associated
with a better prognosis. E-cadherin  is considered as a
prognosis factor in some cancers [38], and we also found
that high E-cadherin  expression was associated with a
better prognosis in univariate analyses of macro-dis-
sected FFPE pancreatic cancer samples but not in multi-
variate analyses (data not shown). These findings indicate
that E-cadherin can be used as a prognosis factor by
immunohistochemistry to detect E-cadherin protein or
by qRT-PCR to measure E-cadherin mRNA levels. How-
ever, it is difficult to generate a highly specific E-cadherin
protein antibody or specific E-cadherin mRNA primers,
especially when using fragmented RNA from FFPE sam-
ples. miRNAs are small RNAs of 14 -24 nucleotides and
are more stable than mRNA from FFPE samples [39] and
the technologies of miRNA extraction and of qRT-PCR
can be controlled more easily than those for mRNAs.
Taken together, these findings suggest that miR-200c can
be a better independent prognosis factor than E-cadherin
mRNA in univariate or multivariate analyses, while the
latter can be used as a prognosis factor in univariate anal-
yses only. Furthermore, Mitchell, et al. reported that cir-
culating miRNAs are stable blood-based markers for
cancer detection [40], suggesting that quantifying the lev-
els of miR-200c from patients' pancreatic juice or blood
may provide an important marker for indicating the suit-
ability for surgery.
Figure 4 Upregulation of miR-200c stimulated proliferation and inhibited invasion. a. the upregulation of mature miR-200c expression en-
hanced the cell proliferation in an upregulation rate-dependent manner in SUIT-2 (upper), KP-3 (middle), and PANC-1 (bottom) cells. b and d. Pictures 
of invading cells (PANC-1 and KP-3, respectively). Original magnification, 10 ×. c and e. The number of invading cells (PANC-1 and KP-3, respectively) 
in five randomly selected fields observed under a light microscope (H&E staining, magnification, 400 ×). Error bars represent SD.
a b
c
d
eYu et al. Molecular Cancer 2010, 9:169
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In conclusion, our results have revealed that high levels
of miR-200c expression inhibit cancer invasion and stim-
ulate cancer cell proliferation, possibly via up-regulation
of E-cadherin, and that high levels of miR-200c expres-
sion correlate with better survival of patients with cura-
tive resection of pancreatic cancer. We believe that
research into miR-200c may bring about new opportuni-
ties for the development of drugs and therapeutic strate-
gies for the treatment of pancreatic cancer. On the other
hand, the miR-200 family members, like miR-200a/b/c,
miR-141, and miR-429, have similar, but not identical
functions ([19,20] and [36]). We believe that it is neces-
sary to investigate the other family members to complete
the picture regarding the miR-200 family and pancreatic
cancer.
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